Biohaven Hits 5-Day High Amid Insider Buying Surge
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 18 Nov 25
Source: Coinmarketcap
Shares of Biohaven Ltd. (BHVN.N) reached a 5-day high today, buoyed by positive insider trading activity. Director Gregory Bailey's recent purchase of 400,000 shares at $7.50 each, totaling $3 million, has contributed to a 17.1% gain from a trading high of $8.79. This surge in stock price reflects growing investor confidence, despite the company reporting a net loss of $173.4 million in Q3 2025. Analysts maintain a 'Market Perform' rating, noting the FDA's Complete Response Letter for Vyglxia as a critical factor in Biohaven's strategic pipeline. With $263.8 million in cash and reduced R&D expenses, the company is focusing on key projects, positioning itself as a noteworthy player in the biotech sector.
Analyst Views on BHVN
Wall Street analysts forecast BHVN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BHVN is 15.09 USD with a low forecast of 9.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Analyst Rating
8 Buy
6 Hold
0 Sell
Moderate Buy
Current: 12.100
Low
9.00
Averages
15.09
High
30.00
Current: 12.100
Low
9.00
Averages
15.09
High
30.00
About BHVN
Biohaven Ltd. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. It is advancing its portfolio of therapeutics, leveraging its drug development experience and multiple proprietary drug development platforms. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; antibody recruiting bispecific molecules; and antibody drug conjugates for cancer. Its advanced product candidate from its glutamate receptor antagonist platform is troriluzole.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
